Other steric antagonists have been developed, namely FLLL32, which block STAT3 dimerization and activation, and have been shown to inhibit tumor growth and angiogenesis in subcutaneous breast cancer xenograft models [327], however further testing of this molecule clinically has not been reported. The gene discussed is STAT3; the disease is neoplasm.